Pharmaceutical Technology

NOVEMBER 13, 2023

An upcoming two-day event will host talks on the impact of new technology on oncology trials and smaller biotechs.

52

52

World Pharma News

JUNE 28, 2023

This afternoon at 2 pm CET (8 am EDT), Bayer AG will host its Pharmaceuticals R&D Event 2023 for Investors. The company will present a deep dive on the innovation strategy in its four therapeutic core areas Oncology, Cardiovascular Diseases, Neurology & Rare Diseases and Immunology.

80

80

European Pharmaceutical Review

APRIL 5, 2024

A 70 percent reduction in the risk of metabolic decompensation events was reported by eight participants in the 12-month pretreatment period, according to the trial results published in Nature. A novel mRNA therapy mRNA-3927 is a novel lipid nanoparticle (LNP)-encapsulated dual investigational mRNA therapy. By encoding for the PCC enzyme.

Vaccines 92

Vaccines 92

InCrowd

APRIL 30, 2024

Attendance Outlook: An impressive 72% of oncologists, whether attending in-person or virtually, are gearing up for ASCO 2024, underscoring the event’s importance in the oncology community. Exciting Topics on the Horizon Topics ranging from groundbreaking research to innovative therapies have captured the interest of oncologists.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Drug Channels

NOVEMBER 14, 2023

It’s time for our most popular event of the year! Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. Dr. Adam J. to 1:30 p.m.

Drug Pricing 75

Drug Pricing Biosimilars 75

Pharmaceutical Business Review

AUGUST 23, 2023

The sNDA is being reviewed under two initiatives of the FDA , the Real-Time Oncology Review programme and Project Orbis. Some of the most common adverse events observed in this group included fatigue, hot flush, and arthralgia. This demonstrates that XTANDI plus leuprolide arm met the primary endpoint of metastasis-free survival (MFS).

96

96

pharmaphorum

AUGUST 24, 2020

Could collecting, understanding, and disseminating patient-reported outcomes during trials be the key to advancing oncology treatments and improving cancer outcomes? . Project Patient Voice is a dedicated online platform that makes patient-reported symptoms and adverse events (AEs) from the trial data of marketed drugs publicly available.

Labelling 127

Labelling Communication Drug Development 127

Express Pharma

DECEMBER 13, 2023

This will ensure a comprehensive database of adverse events including malignancies, if any in the local population, thereby ensuring patient safety in the country. However, regulatory focus on malignancy data might extend clinical trial timelines and increase costs for pipeline therapies, says GlobalData.

Adverse Reactions 102

Adverse Reactions 102

Pharmaceutical Business Review

AUGUST 22, 2023

Some of the most common adverse events reported during the study include hypogammaglobulinaemia, dysgeusia, cytokine release syndrome, and nail disorders. Both the groups receiving a median of five (range, 2-17) prior lines showed meaningful overall response rates.

97

97

pharmaphorum

SEPTEMBER 30, 2022

Genetic testing has become vastly more accessible in the last 20 years and has opened all kinds of doors in medicine, from pharmacogenetics and better understanding drug interactions and adverse events to tremendous advances in oncology: understanding the underlying genetics of cancer cells has allowed delivery of affective, targeted treatments.

98

98

Putting Patients First Blog

MAY 26, 2023

Biosimilars briefing Event Time: 2:00 - 3:00 p.m. ET Event Location: Virtual The National Health Council invites you to join us for a webinar on the latest developments with biosimilars on Monday, June 12 at 2 p.m. If you have registration questions, please contact Racquel Codling at rcodling@nhcouncil.org.

Biosimilars 52

Biosimilars Communication 52

European Pharmaceutical Review

OCTOBER 18, 2022

The ZUMA-7 study demonstrated that treated patients had a four-fold greater improvement in the primary endpoint of event-free survival over the current SOC (8.3 3 cytokine release syndrome (CRS) and neurologic events were observed in 6 percent and 21 percent of patients, respectively. No Grade 5 CRS or neurologic events occurred.

Chemotherapy 104

Chemotherapy 104

Pharmaceutical Technology

AUGUST 8, 2022

Time to progression in pain, castration-resistant prostate cancer, first symptomatic skeletal event, the commencement of successive anticancer treatment, all analysed at 12?week week intervals, as well as adverse events (AEs) as a measure of safety and tolerability were the trial’s secondary endpoints.

Chemotherapy 98

Chemotherapy 98

pharmaphorum

NOVEMBER 15, 2021

Arriving at a critical point for TIGIT development, the 2nd Annual TIGIT Therapies Summit is the definitive industry-led event focused on propelling this next-generation inhibitor to clinical use. Plus 2 add on workshops: • Elucidating the anti-tumor immunity of other immune checkpoint inhibitors in oncology.

Medical Schools 52

Medical Schools Immunity Immunization Hospitals 52

LifeProNow

APRIL 25, 2023

The results were presented on 27 March 2023 at a European Society for Medical Oncology Virtual Plenary and the Society of Gynecologic Oncology Annual Meeting and simultaneously published in The New England Journal of Medicine. GSK in oncology GSK is committed to maximising patient survival through transformational medicines.

Chemotherapy 130

Chemotherapy 130

Putting Patients First Blog

MARCH 8, 2024

One of four annual NHC marquee events, SPES explores how the science of patient engagement is evolving and generating new evidence. Public Affairs and Patient Advocacy, Oncology, Sanofi Kapil Parakh, MD, MPH, PhD , Senior Medical Lead, Google This year, the two-day Symposium will be held at the National Press Club in Washington, DC.

Communication 59

Communication 59

European Pharmaceutical Review

JANUARY 10, 2024

“It is early, but we saw some promising results that this vaccine may help many of these patients avoid relapse, which could increase survival,” principal investigator Dr Shubham Pant, Associate Professor of Gastrointestinal Medical Oncology, explained. “It It also showed a favourable safety profile, which is exciting.”

Vaccines 90

Vaccines Chemotherapy 90

European Pharmaceutical Review

JUNE 6, 2023

These results were presented in an abstract at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Adverse events at Grade 3 or higher from all causes occurred in 23 percent of patients in the TAGRISSO arm versus 14 percent in the placebo arm.

95

95

pharmaphorum

APRIL 6, 2021

With high stakes to satisfy unmet patient needs, cell therapy is a promising but challenging field of oncology. Taking place as a fully interactive digital event, this is y our chance to hear the latest advances and innovations in the preclinical cell therapy space. There is a crucial need to progress candidates from bench to bedside.

Clinical Pharmacology 52

Clinical Pharmacology Medical Schools 52

European Pharmaceutical Review

FEBRUARY 15, 2023

The results suggest “that neoadjuvant nivolumab was safe in long-term follow-up,” commented Patrick Forde, MBBCh, an Associate Professor of oncology and Director of the Thoracic Oncology Clinical Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Neoadjuvant nivolumab did not lead to surgical delays.

Chemotherapy 91

Chemotherapy Immunity Immunization 91

pharmaphorum

NOVEMBER 17, 2020

Are you interested in finding the next breakthrough in immuno-oncology preclinical or clinical development? Recent scientific, clinical breakthroughs and high-profile industry deals have reignited the race to find the next blockbuster TGF-ß inhibitor for immuno-oncology applications. Take a look at the full program here.

Drug Development 52

Drug Development 52

Viseven

OCTOBER 5, 2023

Digital Pharma East is a captivating event for professionals who want to improve their expertise in advertising, sales, brand marketing, customer experience, digital marketing, PR, product marketing, social media, and strategic operations. For Viseven, it was a big honor to attend the event as one of the bronze partners.

52

52

Pharmacy Times

MAY 9, 2023

FCS president and managing physician Lucio Gordan, MD, is a featured speaker at nationwide oncology event to discuss how genetics are advancing cancer care.

26

26

LifeProNow

MARCH 20, 2023

We are therefore delighted that patients in China will now have a new treatment option for metastatic hormone-sensitive prostate cancer that delays disease progression, extends survival and maintains quality of life”, said Christine Roth, Member of the Executive Committee of Bayer’s Pharmaceuticals Division and Head of the Oncology SBU at Bayer.

Compounding 100

Compounding Pharmaceutical Companies Pharmaceutical Companies 100

pharmaphorum

DECEMBER 8, 2022

See the complete 2023 event guide here. Our line-up of 20+ industry leading expert speakers includes: Vicky Appleman , STING Discovery Lead (Principal Scientist), Takeda Oncology. James Palacino , Vice President, Head of Biology, Orum Therapeutics. Oxana Beskrovnaya , Chief Scientific Officer, Dyne Therapeutics.

Drug Development 52

Drug Development 52

pharmaphorum

APRIL 19, 2022

With Keynote sessions from Ikena Oncology, Spring Works Therapeutics, Cedilla and Vivace Therapeutics, this is a unique opportunity to hear first-hand the development of novel YAP/TAZ-TEAD antagonists, from discovery to the clinic. Download the full event guide here.

Drug Development 52

Drug Development 52

pharmaphorum

APRIL 20, 2021

View the event guide now for the full agenda details and expert speaker faculty. Dive into the exciting advancements in the NSCLC rare mutations space, with the novel therapies in targeting BRAF, NGR1 fusions and HER2 with Kinnate Biopharmaceuticals, Elevation Oncology and Boeringer Ingelheim.

Drug Development 52

Drug Development Medical Schools Immunity Immunization 52

pharmaphorum

MAY 27, 2022

With this, there has never been a hotter time to double down and deliver the holy grail of precision oncology as the true power of bispecifics is recognized. Download the Full Event Guide here for speakers, presentations, pricing and more. The post 13th World Multispecifics Summit appeared first on.

Immunity 52

Immunity Immunization 52

pharmaphorum

NOVEMBER 11, 2022

Download the full event guide here for the official agenda. Marc Pelletier , Senior Principal Scientist – Translational Immune Oncology, Novartis. Download your event guide to see what these experts will be discussing. Alan Watt , Chief Scientific Officer, NodThera.

Medical Schools 52

Medical Schools Immunity Immunization Hospitals 52

Pharmaceutical Technology

SEPTEMBER 5, 2022

Soriot said AstraZeneca is particularly interested in oncology, cardiovascular disease, and rare diseases, and taking part in more ‘small to mid-size’ bolt-on acquisitions in the upcoming years. “We In this period, AstraZeneca has also taken part in five oncology and respiratory disease deals, respectively. billion in development.

Vaccines 114

Vaccines 114

pharmaphorum

OCTOBER 13, 2021

The Gastrointestinal Cancer Drug Development Summit is the only biopharma-led conference dedicated to identifying and progressing therapeutic opportunities in targeted and immunotherapies, ADCs, and precision oncology to address the large unmet clinical need in GI cancers. Explore the full event guide here: [link]. **A

Drug Development 52

Drug Development Immunity Immunization 52

European Pharmaceutical Review

NOVEMBER 7, 2022

“The FDA’s Breakthrough Designation recognises the potential of elranatamab as an innovative medicine for multiple myeloma (MM) which has relapsed or is refractory to existing treatments,” shared Dr Chris Boshoff, Chief Development Officer for Oncology and Rare Disease at Pfizer Global Product Development. Elranatamab clinical trial data.

98

98

LifeProNow

MARCH 27, 2023

Slamon, MD, Director of Clinical/Translational Research, University of California, Los Angeles Jonsson Comprehensive Cancer Center and Chairman and Executive Director of Translational Research In Oncology (TRIO) and NATALEE trial lead investigator.

Chemotherapy 130

Chemotherapy Labelling Drug Development 130

Express Pharma

NOVEMBER 15, 2023

According to GlobalData’s 2022 Thematic Research Report on Precision and Personalised Medicine, precision and personalised medicine is most often used in oncology. The most serious adverse event from this trial was that two out of the ten participants experienced heart attacks—including one who died from the heart attack five weeks later.

Compounding 101

Compounding 101

pharmaphorum

MARCH 22, 2021

Focus on Cell Characterization & Beyond Oncology – join a dedicated post-event day to explore preclinical characterization to CMC gold standards and debate the best indications for CAR-TCR technologies with the pioneers pushing the bounds of therapeutic application.

Drug Development 52

Drug Development 52

Drug Channels

MAY 9, 2022

Delivered as a Hybrid Event. This important event convenes key stakeholders including manufacturers, specialty pharmacies, hub providers and more for unrivaled collaboration to leverage innovation and optimize access. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net).

Specialty Pharmacies 68

Specialty Pharmacies 68

European Pharmaceutical Review

AUGUST 17, 2022

The incidence of adverse events, including those of grade 3 or higher, during treatment was higher in the lutetium ( 177 Lu) vipivotide tetraxetan plus SOC group than in the SOC only group11. The most common treatment-emergent adverse events in those receiving lutetium ( 177 Lu) vipivotide tetraxetan plus SOC (all grades) were fatigue (43.1

Chemotherapy 116

Chemotherapy Compounding Labelling 116